home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9604b.zip
/
M9640753.TXT
< prev
next >
Wrap
Text File
|
1996-03-04
|
3KB
|
47 lines
Document 0753
DOCN M9640753
TI Will preventive HIV vaccine efficacy trials be possible with female
injection drug users?
DT 9604
AU Meyers K; Metzger DS; McLellan AT; Navaline H; Sheon AR; Woody GE;
University of Pennsylvania/Philadelphia Veterans Medical Center,; Center
for Studies of Addiction, USA.
SO J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):577-85.
Unique Identifier : AIDSLINE MED/96142221
AB This article examines whether preventive HIV vaccines trials will be
viable among female injection drug users (IDUs). Of the 137 women who
completed baseline serologic and behavioral assessments, 121 (88%) were
seronegative; all enrolled in Project Jumpstart in Philadelphia (PA,
U.S.A.), a vaccine preparedness initiative cosponsored by NIAID and
NIDA. Subjects were seen every 3 months for risk and vaccine opinion
assessment, risk reduction counseling, and HIV antibody testing. The
baseline prevalence rate of HIV infection was 12% (16 of 137) with an
annual incidence rate of 3.5% (4 of 114) during the first year. Of the
121 baseline seronegative women, 28% shared needles and 52% engaged in
unprotected intercourse. Sixty percent of the baseline seronegative
women reported being willing to be one of the first people to try an HIV
vaccine. According to logistic regression, needle sharers were 12.8
times more likely, women who engaged in sex for drugs or money 6.6 times
more likely, out-of-treatment women 3.5 times more likely, and those who
believed that vaccines can prevent disease acquisition 3 times more
likely to report willingness to try an HIV vaccine than their respective
counterparts. At 1-year postbaseline assessment, 98% of the women had
behavioral data collected and 95% had serologic specimens collected.
Given that seroconversions occur and that these women engage in risk
behaviors, report willingness to try an HIV vaccine, and can be retained
for longitudinal assessment, they appear to be suitable participants for
preventive HIV vaccine efficacy trials. Nonetheless, work is required to
insure that these women make informed and knowledgeable decisions
regarding trial enrollment.
DE Adult Aged AIDS Vaccines/*ADMINISTRATION & DOSAGE Clinical
Trials/*STATISTICS & NUMER DATA Cohort Studies Female Human HIV
Antibodies/ANALYSIS HIV Infections/EPIDEMIOLOGY/IMMUNOLOGY/*PREVENTION
& CONTROL HIV Seroprevalence/TRENDS *HIV-1 Incidence Male Middle
Age Patient Compliance Philadelphia/EPIDEMIOLOGY Prevalence
Risk-Taking Substance Abuse, Intravenous/*COMPLICATIONS/PSYCHOLOGY
Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).